Mekinist (trametinib) — Medica

Initial criteria

• Patient has locally advanced or metastatic anaplastic disease
• Patient has BRAF V600 mutation-positive disease
• The medication will be taken in combination with Tafinlar (dabrafenib)

Approval duration

1 year